Northwest Biotherapeutics, Inc. (NWBO)

OTCMKTS · Delayed Price · Currency is USD
0.280
-0.020 (-6.67%)
Dec 11, 2024, 4:00 PM EST
-61.70%
Market Cap 365.33M
Revenue (ttm) 1.60M
Net Income (ttm) -71.01M
Shares Out 1.31B
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,567,500
Open 0.300
Previous Close 0.300
Day's Range 0.280 - 0.310
52-Week Range 0.240 - 0.860
Beta -0.59
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 25
Stock Exchange OTCMKTS
Ticker Symbol NWBO
Full Company Profile

Financial Performance

In 2023, Northwest Biotherapeutics's revenue was $1.93 million, an increase of 14.80% compared to the previous year's $1.68 million. Losses were -$64.37 million, -38.71% less than in 2022.

Financial Statements

News

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities

Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, Md. , July 3, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company de...

5 months ago - PRNewsWire

Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property

Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, Md. , June 17, 2024 /PRNewswire/ -- Northwest Biotherapeutics (...

6 months ago - PRNewsWire

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

BETHESDA, Md. , March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...

9 months ago - PRNewsWire

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

Accompanied by Broad Patent Coverage BETHESDA, Md. , Feb. 6, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune ther...

11 months ago - PRNewsWire

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

Culmination Of Over 20 Years Of Research And Clinical Development BETHESDA, Md. , Dec. 21, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing D...

1 year ago - PRNewsWire

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

BETHESDA, Md. , Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...

1 year ago - PRNewsWire

Northwest Bio: Another Small Filing Delay

Northwest Bio has provided a timeline for submitting an application for approval to the UK equivalent of the US FDA for their GBM therapy. The company has made significant progress in preparing the Ma...

1 year ago - Seeking Alpha

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

BETHESDA, Md. , Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provi...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

BETHESDA, Md. , Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, anno...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

BETHESDA, Md. , Aug. 29, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, annou...

1 year ago - PRNewsWire

Northwest Bio: Is There Ever Going To Be A Right Time?

Northwest Biotherapeutics is a biotech focused on developing a dendritic cell vaccine to fight cancer. The company has faced financial challenges and has relied on dilution to raise funds. While they ...

1 year ago - Seeking Alpha

Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products; Allows Global Delivery of the Products BETHESDA, Md., March 20, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQ...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB

BETHESDA, Md. , March 11, 2023 /PRNewswire/ --  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, tod...

1 year ago - PRNewsWire

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast BETHESDA, Md. , Jan. 6, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing ...

2 years ago - PRNewsWire

Biotech Company Says Citadel, Other Big Traders Manipulated Its Stock Price

In a new lawsuit, Northwest Biotherapeutics accused market makers of illicit “spoofing” trades.

2 years ago - WSJ

Northwest Biotherapeutics: Data Is Done, Just Wait For Approval

NWBO published topline data on JAMA Oncology, resoundingly, I must say. Data shows stat sig on all major primary and secondary endpoints.

2 years ago - Seeking Alpha

Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

Both Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma Results Featured In JAMA Oncology Peer Reviewed Publication    BETHESDA, Md....

2 years ago - PRNewsWire

Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients BETHESDA, Md. , Aug. 23, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a bi...

2 years ago - PRNewsWire

Northwest Biotherapeutics: Another Quarter Of Silence

As is its wont, Northwest Biotherapeutics "progresses" at a snail's pace. NWBO stock is stagnant after that brief spurt in May.

2 years ago - Seeking Alpha

Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility

Application Package Developed By Advent BioServices; Builds on Licenses Obtained in 2021 BETHESDA, Md. , July 6, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnolog...

2 years ago - PRNewsWire

Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program

BETHESDA, Md. , June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, report...

2 years ago - PRNewsWire

Northwest Bio: Buy Again, Wait For Regulatory Process

Data is excellent. I explain the bearish commentary here.

2 years ago - Seeking Alpha

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

BETHESDA, Md. , May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, report...

2 years ago - PRNewsWire

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

BETHESDA, Md. , May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reporte...

2 years ago - PRNewsWire

Northwest Bio: What A Comparison Analysis Says About Its Progress

I have no great opinion about NWBO as a company.

3 years ago - Seeking Alpha